D. E. Shaw & Co., Inc. Revolution Medicines, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 73,657 shares of RVMD stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,657

Previous 51,073 44.22%

Holding current value

$2.72 Million

Previous $1.46 Million 62.09%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.56 - $33.55 $599,831 - $757,693	22,584 Added 44.22%	73,657 $2.37 Million
Q4 2023 Feb 14, 2024	SELL	$18.35 - $34.12 $12.7 Million - $23.7 Million	-694,198 Reduced 93.15%	51,073 $1.46 Million
Q3 2023 Nov 14, 2023	BUY	$25.17 - $35.05 $7.59 Million - $10.6 Million	301,697 Added 68.02%	745,271 $20.6 Million
Q2 2023 Aug 14, 2023	BUY	$20.28 - $27.0 $5 Million - $6.66 Million	246,741 Added 125.36%	443,574 $11.9 Million
Q1 2023 May 15, 2023	BUY	$20.76 - $30.09 $2.8 Million - $4.05 Million	134,759 Added 217.09%	196,833 $4.26 Million

Q4 2022 Feb 14, 2023	SELL	$17.68 - $25.53 $2.23 Million - $3.22 Million	-126,182 Reduced 67.03%	62,074 $1.48 Million
Q3 2022 Nov 14, 2022	BUY	$17.46 - $26.0 $3.29 Million - $4.89 Million	188,256 New	188,256 $3.71 Million
Q1 2022 May 16, 2022	SELL	$17.31 - $26.4 $338,254 - $515,882	-19,541 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$24.35 - $33.7 $475,823 - $658,531	19,541 New	19,541 $492,000
Q3 2021 Nov 15, 2021	SELL	$23.95 - $33.41 $418,933 - $584,407	-17,492 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$29.0 - $47.44 $96,193 - $157,358	-3,317 Reduced 15.94%	17,492 $555,000
Q1 2021 May 17, 2021	BUY	$37.21 - $54.43 $774,302 - $1.13 Million	20,809 New	20,809 $955,000

Others Institutions Holding RVMD

# of Institutions

219

Shares Held

153M

Call Options Held

321K

Put Options Held

111K

View Full List

About Revolution Medicines, Inc.

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.24B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

More about RVMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account